Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-085 in advanced solid tumors
NCT02565758Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2015
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of samrotamab vedotin in solid tumor (advanced stage), undifferentiated pleomorphic sarcoma (UPS), squamous cell carcinoma of the head and neck (HNSCC) and 1 more (2 arms), sponsored by AbbVie Inc. Primary endpoints: Terminal elimination half life at 24 months, Maximum observed plasma concentration at 24 months and 2 more. Started Sep 2015; status: completed.
02
Drugs
samrotamab vedotin
03
Conditions
solid tumor (advanced stage)undifferentiated pleomorphic sarcoma (UPS)squamous cell carcinoma of the head and neck (HNSCC)breast cancer
Beyond the preview
Go deeper on NCT02565758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565758.